GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B1368 Tizanidine HClSummary: α2-adrenergic receptor agonist -
B1073 Tranilast SodiumSummary: Antiallergic agent -
B2251 NaratriptanTarget: 5-HT1 ReceptorSummary: selective 5-HT1 receptor subtype agonist -
B1341 NebivololSummary: Highly selective β1-adrenoceptor antagonist -
B1787 MethyldopaSummary: alpha-2 adrenergic receptor agonist -
B1064 L-(-)-α-Methyldopa (hydrate)Summary: Alpha-adrenergic agonist -
B2261 ZolmitriptanSummary: Potent 5-HT1B/1D/1F agonist -
B2081 MeprednisoneSummary: Glucocorticoid receptor (GR) agonist -
B2158 DesonideSummary: nonfluorinated corticosteroid anti-inflammatory agent -
B1330 Acebutolol HClSummary: β-adrenergic receptors antagonist

